Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 15, 2017. The report discloses a transaction notification regarding conditional share awards granted to a Person Discharging Managerial Responsibilities (PDMR) under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on a specific executive compensation transaction.
| Metric | Value |
|---|---|
| Transaction Date | March 14, 2017 |
| Instrument | American Depositary Shares (ADSs) |
| Price per Share | $41.61 |
| Total Volume | 4,174 ADSs |
| Transaction Type | Acquisition of post-tax Co-investment ADSs and Matching Award conditional ADSs |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It details the execution of a standard executive compensation plan component for Mr. B McNamara, CEO of Consumer Healthcare.
Guidance, Outlook, and Risks
Management Commentary: The awards are subject to performance measures over a three-year period from January 1, 2017, to December 31, 2019. Specific performance measures will be confirmed later in the year following shareholder approval of the Remuneration Policy.
Contingencies: The actual payout is contingent on the achievement of performance targets. The vesting date is the later of the determination date following the performance period, the third anniversary of the award date, or a date determined by the Remuneration Committee.
Risks: The filing notes that the amounts shown are maximum amounts payable exclusive of dividend reinvestment; actual pay-out depends on performance.
Investor Verification Checklist
- Verify the specific performance measures for the 2017-2019 period once confirmed by the Remuneration Committee.
- Confirm the final vesting date and actual payout amount in future Annual Reports.
- Review the shareholder-approved Remuneration Policy for details on the matching award criteria.
- Note that this filing does not contain updated financial results for the quarter or year.